Clinical Trial Update: Loss of RESponse to Ustekinumab Treated by Dose Escalation [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update on patients with Crohn's disease showing loss of response to ustekinumab was addressed by dose escalation; results were posted on …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Stelara (ustekinumab)

Snippet

Sponsor: Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW | Conditions: Crohn Disease | Phase 3 | Status: COMPLETED | Results posted: 2026-04-13